Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy
Mené sur 837 patients atteints d'un carcinome hépatocellulaire de stade avancé (durée médiane de suivi : 15,8 mois), cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, du cabozantinib en combinaison avec l'atézolizumab par rapport à un traitement par sorafénib
The treatment landscape for advanced hepatocellular carcinoma has changed greatly with the introduction of immune checkpoint inhibitors in addition to novel molecularly targeted agents such as anti-PD-1, anti-PD-L1, and anti-VEGF agents. In phase 3 studies, anti-PD-1 and anti-PD-L1 in combination with anti-VEGF or anti-CTLA4 therapies have shown significantly better outcomes as first-line therapies compared with sorafenib.
The Lancet Oncology , commentaire, 2021